This is a preview of subscription content, log in via an institution to check access.
Notes
This profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.
References
Chez MG, Hammer MS, Bagan BT, et al. Secretin used in the treatment of autism: a double-blind clinical trial in children. Annals Neurol 46: 523, Sep 1999
Repligen Corporation. Multi-dose therapy produces statistically significant improvement in symptoms of autism using parental clinical global impression scale. Media Release: [4 pages], 4 Apr 2001. Available from URL: http://www.repligen.com
Repligen Corporation. Repligen announces initiation of phase 3 clinical trials for secretin in autism. Media Release: [2 pages], 14 Feb 2002. Available from URL: http://www.repligen.com
Repligen Corporation. Secretin clinical data presented at Autism Society of American Annual Meeting meta-analysis of four phase 1 studies shows statistically significant treatment effect. Media Release: [4 pages], 20 Jul 2001. Available from URL: http://www.repligen.com
National Institutes of Health. Study confirms secretion no more effective than placebo in treating autism symptoms. Media Release: [3 pages], 27 Nov 2001. Available from URL: http://www.nichd.nih.go
Rights and permissions
About this article
Cite this article
Secretin - Repligen. Drugs R&D 3, 217–219 (2002). https://doi.org/10.2165/00126839-200203030-00018
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-200203030-00018